• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial

    1/30/25 8:00:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JUNS alert in real time by email

    Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Zina Biopharmaceuticals, LLC ("Zina") to support all aspects of Jupiter's upcoming Phase 2a clinical trial for Parkinson's disease.

    Under the terms of the agreement, Zina will provide comprehensive services related to the execution of the exploratory Phase 2a trial evaluating JOTROL™, Jupiter's patented resveratrol-based therapeutic platform. The primary objective of the trial will be to evaluate the safety and tolerability of JOTROL in patients with Parkinson's, with secondary and exploratory endpoints to assess pharmacokinetics/pharmacodynamics (PK/PD) of the drug.

    JOTROL's innovative micellar formulation overcomes the historical limitations of resveratrol by achieving significantly enhanced bioavailability while minimizing gastrointestinal side effects. Preclinical studies have demonstrated JOTROL's potential in mitigating key biomarkers associated with neurodegeneration, supporting its potential application in Parkinson's disease and other central nervous system (CNS) disorders.

    "This partnership with Zina marks a significant milestone for Jupiter as we advance JOTROL into Phase 2 clinical development for Parkinson's," said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. "Zina's extensive expertise in trial execution, as well as regulatory, clinical and scientific strategy, will be instrumental in accelerating our development timeline and positioning us for future pivotal studies."

    Under the agreement, Zina will assist with clinical trial protocol design, including pharmacokinetics and biomarkers, regulatory strategy, and trial site selection to facilitate a smooth trial execution and future clinical progression.

    Parkinson's disease affects over 10 million people worldwide, with no disease-modifying treatments currently available. The global Parkinson's therapeutics market is projected to exceed $14 billion by 2030, highlighting the urgent need for novel interventions. Jupiter Neurosciences remains committed to leveraging JOTROL's unique pharmacological advantages to address this significant unmet medical need.

    Jupiter is actively exploring additional strategic partnerships to expand JOTROL's application across other neuroinflammatory and metabolic disorders, including Alzheimer's disease and longevity medicine.

    About Jupiter Neurosciences, Inc.

    Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website www.jupiterneurosciences.com.

    About JOTROL

    Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.

    Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022.

    About Zina Biopharmaceuticals, LLC

    Zina Biopharmaceuticals is a specialized consulting company providing end-to-end trial design and execution solutions as well as regulatory, scientific and medical advice for biotech and pharmaceutical companies.

    FORWARD-LOOKING STATEMENTS

    Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the use of proceeds from the Offering. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

    Contact:

    Dave Gentry

    RedChip Companies, Inc.

    1-407-644-4256

    1-800-RED-CHIP (733-2447)

    [email protected]



    Primary Logo

    Get the next $JUNS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JUNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JUNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

      Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL™, over conventional resveratrol formulations. Unlocking Resveratrol's Therapeutic Promise Resveratrol is one of the world's most researched molecules and has long been studied for its powerful antioxidant, mitochondrial, and anti-inflammatory effects. However, achieving therapeutic benefit has

      7/23/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

      Nasdaq compliance follows positive upward trend in Company's Stock Price  Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced it has regained compliance with the Nasdaq Stock Market ("Nasdaq") continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company's Current Report on Form 8-K filed on July 10, 2025. On July 9, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as

      7/10/25 4:05:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

      PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to unveil Nugevia™ PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recovery. PWR targets a rapidly expanding consumer demand for science-backed, clinically validated supplements, providing a high-margin growth opportunity within the longevity and wellness markets, proje

      6/30/25 3:15:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 2:53:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:51 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Pres + Chief Business Officer Silva Alison D.

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/7/25 9:28:07 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Secretary Elmasri Saleem converted options into 66,293 shares (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/7/25 9:28:09 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    SEC Filings

    See more
    • Jupiter Neurosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      7/10/25 5:08:19 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      7/9/25 4:40:39 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Jupiter Neurosciences Inc.

      10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      5/15/25 4:31:24 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care